Carcinoembryonic antigen as a vaccine target

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 987-993

  Wang, Dongmei ^b   Rayani, Shayan ^a   Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoembryonic antigen; Immunotherapy; Tumor vaccine

Indexed keywords

ALVAC; ALVAC CARCINOEMBRYONIC ANTIGEN VACCINE; B7 ANTIGEN; CANCER VACCINE; CAP 1 PROTEIN; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN DNA; CARCINOEMBRYONIC ANTIGEN MESSENGER RNA; CARCINOEMBRYONIC ANTIGEN PEPTIDE 610D; CEAVAC; DNA VACCINE; EPITOPE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN DNA; IDIOTYPIC ANTIBODY; IDIOTYPIC ANTIBODY 3H1; IDIOTYPIC ANTIBODY PR1A3; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; IRINOTECAN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METRONIDAZOLE; MONOCLONAL ANTIBODY TRIAB; PANVAC; PANVAC CARCINOEMBRYONIC ANTIGEN VACCINE; PEPTIDE VACCINE; RECOMBINANT CARCINOEMBRYONIC ANTIGEN VACCINE; RECOMBINANT INTERLEUKIN 2; TRICOM CARCINOEMBRYONIC ANTIGEN VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; AUTOIMMUNE DISEASE; CANARYPOX VIRUS; CHILL; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; ERYTHEMA; FATIGUE; FEVER; FOWLPOX VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE DISCOMFORT; INJECTION SITE REACTION; LIVER DYSFUNCTION; LOW DRUG DOSE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; POXVIRUS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INDURATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; HUMANS; NEOPLASMS;

EID: 51349167257     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.987     Document Type: Review

References (40)

1. Benchimol S, Fuks A, Jothy S et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57, 327-332 (1989).
2. Kent SJ, Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-10188 (1998).
3. Taylor J, Trimarchi C, Weinberg R et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9, 190-193 (1991).
4. Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer 48, 900-907 (1991).
5. Kantor J, Irvine K, Abrams S et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 84, 1084-1091 (1992).
6. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87, 982-990 (1995).
7. Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800-5807 (1999).
8. Von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B 7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228 (2000).
9. Lorenz MG, Kantor JA, Schlom J et al. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus. Hum. Gene Ther. 10, 623-631 (1999).
10. Uzendoski K, Kantor JA, Abrams SI et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum. Gene Ther. 8, 851-860 (1997).
11. Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res. 59, 5106-5111 (1999).
12. Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17, 332-337 (1999).
13. Hodge JW, McLaughlin JP, Kantor JA. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 16, 759-768 (1997).
14. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox to elicit anticarcinogenic antigen immune responses. J. Clin. Oncol. 18, 3964-3973 (2000). • Key article establishing both prime and boost and granulocyte-macrophage colony-stimulating factor impact on immune responses.
15. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self antigen and antitumor activity. Cancer Res. 62, 5770-5777 (2002).
16. von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228 (2000).
17. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox -CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23, 720-731 (2005). • Key article establishing costimulatory molecules and tumor burden impact on immune responses.
18. Taylor-Papadimitriou J, Burchell JM, Plunkett T et al. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 7, 209-221 (2002).
19. Hiltbold EM, Alter MD, Ciborowski P et al. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. 194, 143-149 (1999).
20. Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).
21. Gulley JK, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxvirus-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060-3069 (2008).
22. Jerne NK. Towards a network theory of the immune system. Ann. Immunology 125C, 373-389 (1974).
23. Lindenmann J. Speculations on idiotypes and homobodies. Ann. Immunology 124, 171-184 (1973).
24. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W et al. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J. Immunol. 145(8), 2758-2765 (1990).
25. Foon KA, Chakraborty M, John WJ et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. 96(1), 334-342 (1995).
26. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res. 3(8), 1267-1276 (1997).
27. Zbar AP, Thomas H, Wilkinson RW et al. Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a Phase I study. Int. J. Colorectal Dis. 20(5), 403-414 (2005).
28. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17(9), 2889-2895 (1999).
29. Posner MC, Niedzwiecki D, Venook AP et al. A Phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann. Surg. Oncol. 15(1), 158-164 (2008). • Demonstrates the selection of proper patients.
30. Saha A, Chatterjee SK, Foon KA et al. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res. 63(11), 2844-2854 (2003). • Highlights the importance of dendritic cells.
31. Saha A, Baral RN, Chatterjee SK et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol. Immunother. 55(5), 515-527 (2006).
32. Saha A, Chatterjee SK, Foon KA et al. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res. 67(6), 2881-2892 (2007).
33. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87(13), 982-990 (1995).
34. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5(6), 1331-1338 (1999). • Highlights the clinical utility of dendritic cells.
35. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98(15), 8809-8814 (2001).
36. Weihrauch MR, Ansén S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 11(16), 5993-6001 (2005).
37. Ullenhag GJ, Frödin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res. 10(10), 3273-3281 (2004).
38. Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21(3), 341-349 (2003).
39. Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8(9), 2782-2787 (2002).
40. Cole DJ, Baron PL, O'Brien P et al. Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost. Clin. Lung Cancer 1(3), 227-229 (2000).